Accéder au contenu
Merck

Phenotypic heterogeneity enables uropathogenic Escherichia coli to evade killing by antibiotics and serum complement.

Infection and immunity (2015-01-07)
Marta Putrinš, Karin Kogermann, Eliisa Lukk, Markus Lippus, Vallo Varik, Tanel Tenson
RÉSUMÉ

Uropathogenic strains of Escherichia coli (UPEC) are the major cause of bacteremic urinary tract infections. Survival in the bloodstream is associated with different mechanisms that help to resist serum complement-mediated killing. While the phenotypic heterogeneity of bacteria has been shown to influence antibiotic tolerance, the possibility that it makes cells refractory to killing by the immune system has not been experimentally tested. In the present study we sought to determine whether the heterogeneity of bacterial cultures is relevant to bacterial targeting by the serum complement system. We monitored cell divisions in the UPEC strain CFT073 with fluorescent reporter protein. Stationary-phase cells were incubated in active or heat-inactivated human serum in the presence or absence of different antibiotics (ampicillin, norfloxacin, and amikacin), and cell division and complement protein C3 binding were measured by flow cytometry and immunofluorescence microscopy. Heterogeneity in the doubling times of CFT073 cells in serum enabled three phenotypically different subpopulations to be distinguished, all of them being recognized by the C3 component of the complement system. The population of rapidly growing cells resists serum complement-mediated lysis. The dominant subpopulation of cells with intermediate growth rate is susceptible to serum. The third population, which does not resume growth upon dilution from stationary phase, is simultaneously protected from serum complement and antibiotics.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Glycérol, ACS reagent, ≥99.5%
Sigma-Aldrich
Glycérol, for molecular biology, ≥99.0%
Sigma-Aldrich
Glycérol, ReagentPlus®, ≥99.0% (GC)
Sigma-Aldrich
Chloramphénicol, ≥98% (HPLC)
Sigma-Aldrich
Ampicilline sodium salt, powder or crystals, BioReagent, suitable for cell culture
Sigma-Aldrich
Ampicilline sodium salt
Sigma-Aldrich
Glycérol solution, 83.5-89.5% (T)
Sigma-Aldrich
Glycérol, ≥99.5%
Sigma-Aldrich
Glycérol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for electrophoresis, ≥99% (GC)
Sigma-Aldrich
Glycérol, BioUltra, for molecular biology, anhydrous, ≥99.5% (GC)
USP
Glycérine, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Glycérol, FCC, FG
Sigma-Aldrich
Chloramphénicol, BioReagent, suitable for plant cell culture
Sigma-Aldrich
Ampicilline sodium salt, BioXtra, suitable for cell culture
Supelco
Glycérol, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Glycérol, BioXtra, ≥99% (GC)
Sigma-Aldrich
Glycérine, meets USP testing specifications
Sigma-Aldrich
Chloramphénicol, meets USP testing specifications
USP
Amikacin, United States Pharmacopeia (USP) Reference Standard
Supelco
Glycérol, analytical standard
Sigma-Aldrich
Glycérol, tested according to Ph. Eur., anhydrous
Supelco
Chloramphénicol, VETRANAL®, analytical standard
Supelco
Norfloxacin, analytical standard, ≥98% (TLC)
USP
Ampicilline sodium salt, United States Pharmacopeia (USP) Reference Standard
Supelco
Ampicilline sodium salt, Pharmaceutical Secondary Standard; Certified Reference Material
Chloramphénicol, European Pharmacopoeia (EP) Reference Standard
Supelco
Norfloxacin, VETRANAL®, analytical standard
Amikacin, European Pharmacopoeia (EP) Reference Standard
Norfloxacin, European Pharmacopoeia (EP) Reference Standard
Norfloxacin for system suitability, European Pharmacopoeia (EP) Reference Standard